-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $12

Benzinga·05/05/2025 17:21:27
Listen to the news
Barclays analyst Matt Miksic maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and lowers the price target from $16 to $12.